L-364,718, a new CCK antagonist, inhibits postprandial pancreatic secretion and PP release in dogs.
The effects of L-364,718, a new CCK receptor antagonist, on food-stimulated exocrine pancreatic secretion and plasma levels of PP, insulin, CCK, and gastrin were examined in four conscious dogs with pancreatic fistulas. Intravenous injections of L-364,718 (20 nmol/kg) significantly inhibited pancreatic protein and enzyme responses by food (33% inhibition) but not juice volume output. Both rapid and secondary prolonged postprandial rises of plasma PP were also significantly suppressed by L-364,718 (50% inhibition); however, plasma levels of insulin were not altered. Postprandial levels of gastrin were not affected by L-364,718 administration, whereas 3-hr integrated CCK response was significantly enhanced by L-364,718. This study indicates that L-364,718 inhibits pancreatic protein and enzyme secretion and the release of pancreatic polypeptide stimulated by food in conscious dogs. This inhibition might be due to the selective blockage of receptor binding of circulating CCK molecules. The results suggest that L-364,718 may be useful for the physiological and pathophysiological studies associated with CCK.
Hosotani
R
R
Department of Physiology and Biophysics, University of Arkansas for Medical Sciences, Little Rock 72205.
Chowdhury
P
P
Rayford
P L
PL
D000818:Animals; D001570:Benzodiazepinones / Q000494:pharmacology*; D002766:Cholecystokinin / Q000037:antagonists & inhibitors* / Q000378:metabolism; D020109:Devazepide; D004285:Dogs; D004435:Eating; D005755:Gastrins / Q000378:metabolism; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D010179:Pancreas / Q000187:drug effects / Q000378:metabolism*; D010189:Pancreatic Juice / Q000378:metabolism; D010191:Pancreatic Polypeptide / Q000378:metabolism; D011863:Radioimmunoassay
D001570:Benzodiazepinones; D005755:Gastrins; D007328:Insulin; D010191:Pancreatic Polypeptide; D002766:Cholecystokinin; D020109:Devazepide